To achieve robust amorphous solid dispersion (ASD) drug products, pharmaceutical scientists must design these formulations to attain several key attributes.  This includes in vivo performance, stability and manufacturability, all while minimizing dosage form size. Combining knowledge of key drug, polymer and gastrointestinal properties--together with an in vitro and in silico toolkit--is critical for achieving key attributes, while reducing development timelines and drug substance requirements.  To learn more, download our webinar slides.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center